scholarly article | Q13442814 |
P356 | DOI | 10.1517/13543784.2013.820275 |
P8608 | Fatcat ID | release_v3ce73ck5fb5tfqihbljzasudi |
P698 | PubMed publication ID | 23855792 |
P50 | author | Serena Ruggieri | Q56987509 |
Claudio Gasperini | Q57443880 | ||
P2093 | author name string | Shalom Haggiag | |
P2860 | cites work | IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel | Q24646531 |
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 | ||
Ocrelizumab: a step forward in the evolution of B-cell therapy | Q28245986 | ||
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis | Q28268626 | ||
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis | Q28270998 | ||
The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability | Q28284428 | ||
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group | Q28293763 | ||
Multiple sclerosis | Q28299151 | ||
IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome | Q28750403 | ||
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination | Q29614990 | ||
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis | Q29616119 | ||
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project | Q33383576 | ||
Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. | Q33565842 | ||
High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect | Q33590797 | ||
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. | Q33899917 | ||
Multiple sclerosis: distribution of inflammatory cells in newly forming lesions | Q34089994 | ||
Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology | Q34096238 | ||
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial | Q34229618 | ||
Risk of natalizumab-associated progressive multifocal leukoencephalopathy | Q34275329 | ||
Diagnosis and treatment of multiple sclerosis | Q34421883 | ||
Revised diagnostic criteria for neuromyelitis optica | Q34529345 | ||
Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies | Q34619483 | ||
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients | Q34823634 | ||
CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation | Q36161486 | ||
The immunology of multiple sclerosis | Q37078984 | ||
The pathological spectrum of CNS inflammatory demyelinating diseases | Q37603085 | ||
Predicting responders to therapies for multiple sclerosis | Q37606292 | ||
CD20 as a target for therapeutic type I and II monoclonal antibodies. | Q37720878 | ||
EFNS guidelines on diagnosis and management of neuromyelitis optica | Q37763266 | ||
Treatment of multiple sclerosis with anti-CD20 antibodies | Q37873643 | ||
Variable results after rituximab in neuromyelitis optica | Q37992354 | ||
The evidence for a role of B cells in multiple sclerosis | Q37993033 | ||
Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. | Q39808939 | ||
Interferon beta-1b | Q40636802 | ||
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial | Q44264108 | ||
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial | Q45119459 | ||
Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. | Q47357498 | ||
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. | Q48200750 | ||
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. | Q48427388 | ||
B-cell depletion abrogates T cell-mediated demyelination in an antibody-nondependent common marmoset experimental autoimmune encephalomyelitis model. | Q48437549 | ||
CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. | Q48898700 | ||
Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis. | Q50944222 | ||
Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
B-cell subsets up-regulate α4 integrin and accumulate in the cerebrospinal fluid in clinically isolated syndrome suggestive of multiple sclerosis onset | Q51033051 | ||
Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. | Q54195610 | ||
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis | Q57753793 | ||
P433 | issue | 10 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | multiple sclerosis | Q8277 |
P304 | page(s) | 1243-1253 | |
P577 | publication date | 2013-07-16 | |
P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
P1476 | title | Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies | |
P478 | volume | 22 |
Q36484383 | Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis |
Q57192334 | Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies |
Q35584727 | The meninges: new therapeutic targets for multiple sclerosis |
Q90531435 | Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies |
Search more.